Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

Docetaxel 4pembrolizumab 2Carboplatin 2tislelizumab 1nazartinib 1lenvatinib 1cemiplimab 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Platinum Compounds 1Pemetrexed 1Nivolumab 1Midazolam 1Gefitinib 1Food 1Esomeprazole 1Dabigatran 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-small Cell Lung Cancer × Docetaxel × Clear all
NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05215067 2025-03-12

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Akeso

Phase 2 Active not recruiting
44 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06775483 2025-01-15

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Not yet recruiting
220 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2/3 Terminated
16 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡